JNCCN 360 - MM - News

Advertisement

Advertisement

News

FDA Approves Teclistamab for Relapsed/Refractory Myeloma

Teclistamab Plus Daratumumab Significantly Prolongs Survival in Relapsed or Refractory Multiple Myeloma

Daratumumab and Hyaluronidase Plus VRd Approved for Newly Diagnosed Multiple Myeloma

Teclistamab Plus Daratumumab Shows Significant Survival Benefit in Relapsed/Refractory Multiple Myeloma

When Is it Safe to Discontinue Maintenance Therapy in Multiple Myeloma?

Whole-Body MRI May Enhance Response Assessment in Newly Diagnosed Multiple Myeloma

Endogenous T-cell Dynamics Predict Response to CAR-T Therapy in Multiple Myeloma

Sections

NCCN Resources

Copyright © 2026 National Comprehensive Cancer Network, All Rights Reserved